PFE VS NVS Stock Comparison
Performance
PFE10/100
10/100
PFE returned -36.05% in the last 12 months. Based on SPY's performance of -21.29%, its performance is below average giving it a score of 10 of 100.
NVS100/100
100/100
NVS returned 11.56% in the last 12 months. Based on SPY's performance of -13.77%, its performance is above average giving it a score of 100 of 100.
Analyst Price Targets
PFE63/100
63/100
22 analysts offer 12-month price targets for PFE. Together, they have an average target of 60.44, the most optimistic target put PFE at 141.39 within 12-months and the most pessimistic has PFE at 44.
NVS67/100
67/100
3 analysts offer 12-month price targets for NVS. Together, they have an average target of 0, the most optimistic target put NVS at 0 within 12-months and the most pessimistic has NVS at 0.
Sentiment
PFE70/100
70/100
PFE had a bullish sentiment score of 69.84% across Twitter and StockTwits over the last 12 months. It had an average of 317.89 posts, 5,792.02 comments, and 19,827.59 likes per day.
NVS
"Sentiment" not found for NVS
Technicals
PFE11/100
11/100
PFE receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.
NVS10/100
10/100
NVS receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.
Earnings
PFE74/100
74/100
PFE has missed earnings 2 times in the last 20 quarters.
NVS39/100
39/100
NVS has missed earnings 5 times in the last 20 quarters.
Profit
PFE68/100
68/100
Out of the last 20 quarters, PFE has had 17 profitable quarters and has increased their profits year over year on 8 of them.
NVS73/100
73/100
Out of the last 20 quarters, NVS has had 20 profitable quarters and has increased their profits year over year on 8 of them.
Volatility
PFE43/100
43/100
PFE has had a lower than average amount of volatility over the last 12 months giving it a score of 42 of 100.
NVS44/100
44/100
NVS has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.
Dividend
PFE97/100
97/100
PFE's most recent dividend was $0.32 per share, based on a share price of $30.11. It was a payout ratio of 48.46% compared to their total earnings.
NVS
"Dividend" not found for NVS
All score calculations are broken down here to help you make more informed investing decisions
Pfizer Inc. Summary
New York Stock Exchange / PFE
Healthcare
Drug Manufacturers - General
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Novartis AG Summary
New York Stock Exchange / NVS
Healthcare
Drug Manufacturers - General
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare PFE to other companies in the same or a similar industry.